A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared with Durvalumab in Patients with Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer who have not Progressed after Concurrent Platinum-Based Chemoradiation (SKYSCRAPER-03)
This research study, called SKYSCRAPER-03, is for people with a type of lung cancer known as non-small cell lung cancer (NSCLC) that is advanced but hasn't spread to other distant parts of the body. Participants have already had chemotherapy and radiotherapy. The study aims to find out if new drug combinations (atezolizumab with tiragolumab, or just durvalumab) are better than standard care at preventing the cancer from growing or coming back. Researchers will compare how long people live without their cancer getting worse and how long they live overall. This is an important step to find more effective treatments for this type of cancer.
At a glance
What is this study about?
This research study is looking for better ways to treat a specific kind of lung cancer called non-small cell lung cancer (NSCLC). This is a common type of lung cancer. The study is for people whose cancer is considered 'locally advanced' – meaning it has grown quite a bit within the chest area, but hasn't spread to distant parts of the body. Importantly, participants in this study would have already received a combination of chemotherapy and radiation treatment, and their cancer would have responded well, meaning it hasn't started growing again after that initial treatment.
The main goal of this study is to see if two different treatment approaches can help keep the cancer from growing or coming back for longer. One approach uses a combination of two drugs, atezolizumab and tiragolumab. The other approach uses a single drug called durvalumab, which is already a common treatment in this situation. Researchers want to compare these treatments to find out which is more effective.
They will be carefully watching how long it takes for the cancer to show signs of growing again – this is called 'progression-free survival'. They will also track how long people live overall. This kind of study helps doctors understand if new treatments are better than existing ones, leading to improved care for patients with this type of lung cancer.
Key takeaways
- This study is for locally advanced non-small cell lung cancer.
- Participants must have completed chemotherapy and radiation without cancer progression.
- It compares two new treatment approaches: atezolizumab + tiragolumab vs. durvalumab.
- The main aim is to see which treatment best stops cancer growth long-term.
- Closer monitoring and regular hospital visits are involved.
Who may be eligible?
To be able to join this study, people typically need to meet certain requirements. First, you must have been diagnosed with non-small cell lung cancer that is locally advanced, meaning it hasn't spread to distant parts of your body.
Also, a key requirement is that you must have already completed a standard course of chemotherapy and radiotherapy for your lung cancer, and your cancer should not have started growing again after these treatments. You need to be at least 18 years old to take part. Both men and women can join the study.
There will also be other health checks and tests to make sure that the study treatments are safe for you and that you meet all the detailed medical requirements. Your doctor will discuss all of these with you carefully.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I have locally advanced non-small cell lung cancer.
- I have finished chemotherapy and radiotherapy for my lung cancer.
- My cancer has not started growing again after those treatments.
- I am at least 18 years old.
What does participation involve?
If you decide to take part in this study, you would receive one of the study treatments, which are given as infusions (like a drip into your vein). You will have regular visits to your clinic or hospital for these treatments and for appointments where doctors and nurses will monitor your health and how the treatment is working. These visits will include various tests, such as scans (like CT scans) to check the size of your cancer, and blood tests to monitor your general health.
The study will follow you closely to see how long your cancer remains stable and how you are feeling. Doctors will also carefully record any side effects you might experience. The total duration of your participation, including treatment and follow-up, will be explained in detail by the study team, but it will involve regular appointments over an extended period.
Potential risks and benefits
Locations (11)
- —UnverifiedPoland
- —UnverifiedSpain
- —UnverifiedPortugal
- —UnverifiedBelgium
- —UnverifiedFrance
- —UnverifiedGreece
- —UnverifiedAustria
- —UnverifiedGermany
- —UnverifiedItaly
- —UnverifiedHungary
- —UnverifiedNetherlands
Common questions
What kind of lung cancer is this study for?
This study is for a specific type of lung cancer called non-small cell lung cancer that is locally advanced.
Do I need to have had treatment before to join?
Yes, you must have already received chemotherapy and radiotherapy and your cancer shouldn't have gotten worse afterwards.
What drugs are being tested?
The study is testing combinations of atezolizumab and tiragolumab against durvalumab, which are all types of immunotherapy.
What will doctors be looking for?
They will mainly be looking at how long your cancer stays stable without growing (progression-free survival) and how long people live overall.
Can I leave the study if I change my mind?
Yes, you can withdraw from the study at any time without it affecting your standard medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.